Pseudoprogression as an adverse event of glioblastoma therapy
We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and...
| Autores: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2017 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:289120 |
| Acceso en línea: | https://ddd.uab.cat/record/289120 https://dx.doi.org/urn:doi:10.1002/cam4.1242 |
| Access Level: | acceso abierto |
| Palabra clave: | MGMT Glioblastoma IDH1 mutation Imaging Pseudoprogression Radionecrosis |
| id |
ES_001cf97103d8b570fdce77faaf7c1eb7 |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:289120 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Pseudoprogression as an adverse event of glioblastoma therapyBalañá, Carmen|||0000-0003-0771-0390Capellades, Jaume|||0000-0002-1417-4496Pineda, Estela|||0000-0003-2128-747XEstival, Anna|||0000-0002-2788-9159Puig, Josep|||0000-0003-2791-6599Domenech, Sira|||0000-0002-5700-768XVerger, EugeniaPujol, TeresaMartinez-García, MariaOleaga, Laura|||0000-0001-9702-0451Velarde, Jose MaríaMesia, CarlosFuentes, RafaelMarruecos, JordiDel Barco Berrón, Sonia|||0000-0002-4951-6871Villà, SalvadorCarrato, Cristina|||0000-0002-1953-8287Gallego Rubio, Oscar|||0000-0001-5665-0967Gil-Gil, Miguel|||0000-0003-1380-2718Craven-Bartle, JordiAlameda, Francesc|||0000-0002-7302-6901MGMTGlioblastomaIDH1 mutationImagingPseudoprogressionRadionecrosisWe explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression-free survival (PFS), post-progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21.9%) were classified as PsP, 70 (27.3%) as eP, and 130 (50.8%) as nP. Only MGMT methylation status was associated to PsP. MGMT methylated patients had a 3.5-fold greater possibility of having PsP than eP (OR: 3.48; 95% CI: 1.606-7.564; P = 0.002). OS was longer for PsP than eP patients (18.9 vs. 12.3 months; P = 0.0001) but was similar for PsP and nP patients (P = 0.91). OS was shorter-though not significantly so-for PsP than nP patients (OS: 19.5 vs. 27.9 months; P = 0.63) in methylated patients. PPS was similar for patients having PsP, eP or nP (PPS: 7.2 vs. 5.4 vs. 6.7; P = 0.43). Neurological deterioration occurred in 64.3% of cases at the time they were classified as PsP and in 72.8% of cases of eP (P = 0.14). PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma.Universitat Autònoma de Barcelona 22017-01-0120172017-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/289120https://dx.doi.org/urn:doi:10.1002/cam4.1242reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2891202026-06-06T12:50:31Z |
| dc.title.none.fl_str_mv |
Pseudoprogression as an adverse event of glioblastoma therapy |
| title |
Pseudoprogression as an adverse event of glioblastoma therapy |
| spellingShingle |
Pseudoprogression as an adverse event of glioblastoma therapy Balañá, Carmen|||0000-0003-0771-0390 MGMT Glioblastoma IDH1 mutation Imaging Pseudoprogression Radionecrosis |
| title_short |
Pseudoprogression as an adverse event of glioblastoma therapy |
| title_full |
Pseudoprogression as an adverse event of glioblastoma therapy |
| title_fullStr |
Pseudoprogression as an adverse event of glioblastoma therapy |
| title_full_unstemmed |
Pseudoprogression as an adverse event of glioblastoma therapy |
| title_sort |
Pseudoprogression as an adverse event of glioblastoma therapy |
| dc.creator.none.fl_str_mv |
Balañá, Carmen|||0000-0003-0771-0390 Capellades, Jaume|||0000-0002-1417-4496 Pineda, Estela|||0000-0003-2128-747X Estival, Anna|||0000-0002-2788-9159 Puig, Josep|||0000-0003-2791-6599 Domenech, Sira|||0000-0002-5700-768X Verger, Eugenia Pujol, Teresa Martinez-García, Maria Oleaga, Laura|||0000-0001-9702-0451 Velarde, Jose María Mesia, Carlos Fuentes, Rafael Marruecos, Jordi Del Barco Berrón, Sonia|||0000-0002-4951-6871 Villà, Salvador Carrato, Cristina|||0000-0002-1953-8287 Gallego Rubio, Oscar|||0000-0001-5665-0967 Gil-Gil, Miguel|||0000-0003-1380-2718 Craven-Bartle, Jordi Alameda, Francesc|||0000-0002-7302-6901 |
| author |
Balañá, Carmen|||0000-0003-0771-0390 |
| author_facet |
Balañá, Carmen|||0000-0003-0771-0390 Capellades, Jaume|||0000-0002-1417-4496 Pineda, Estela|||0000-0003-2128-747X Estival, Anna|||0000-0002-2788-9159 Puig, Josep|||0000-0003-2791-6599 Domenech, Sira|||0000-0002-5700-768X Verger, Eugenia Pujol, Teresa Martinez-García, Maria Oleaga, Laura|||0000-0001-9702-0451 Velarde, Jose María Mesia, Carlos Fuentes, Rafael Marruecos, Jordi Del Barco Berrón, Sonia|||0000-0002-4951-6871 Villà, Salvador Carrato, Cristina|||0000-0002-1953-8287 Gallego Rubio, Oscar|||0000-0001-5665-0967 Gil-Gil, Miguel|||0000-0003-1380-2718 Craven-Bartle, Jordi Alameda, Francesc|||0000-0002-7302-6901 |
| author_role |
author |
| author2 |
Capellades, Jaume|||0000-0002-1417-4496 Pineda, Estela|||0000-0003-2128-747X Estival, Anna|||0000-0002-2788-9159 Puig, Josep|||0000-0003-2791-6599 Domenech, Sira|||0000-0002-5700-768X Verger, Eugenia Pujol, Teresa Martinez-García, Maria Oleaga, Laura|||0000-0001-9702-0451 Velarde, Jose María Mesia, Carlos Fuentes, Rafael Marruecos, Jordi Del Barco Berrón, Sonia|||0000-0002-4951-6871 Villà, Salvador Carrato, Cristina|||0000-0002-1953-8287 Gallego Rubio, Oscar|||0000-0001-5665-0967 Gil-Gil, Miguel|||0000-0003-1380-2718 Craven-Bartle, Jordi Alameda, Francesc|||0000-0002-7302-6901 |
| author2_role |
author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Universitat Autònoma de Barcelona |
| dc.subject.none.fl_str_mv |
MGMT Glioblastoma IDH1 mutation Imaging Pseudoprogression Radionecrosis |
| topic |
MGMT Glioblastoma IDH1 mutation Imaging Pseudoprogression Radionecrosis |
| description |
We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression-free survival (PFS), post-progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21.9%) were classified as PsP, 70 (27.3%) as eP, and 130 (50.8%) as nP. Only MGMT methylation status was associated to PsP. MGMT methylated patients had a 3.5-fold greater possibility of having PsP than eP (OR: 3.48; 95% CI: 1.606-7.564; P = 0.002). OS was longer for PsP than eP patients (18.9 vs. 12.3 months; P = 0.0001) but was similar for PsP and nP patients (P = 0.91). OS was shorter-though not significantly so-for PsP than nP patients (OS: 19.5 vs. 27.9 months; P = 0.63) in methylated patients. PPS was similar for patients having PsP, eP or nP (PPS: 7.2 vs. 5.4 vs. 6.7; P = 0.43). Neurological deterioration occurred in 64.3% of cases at the time they were classified as PsP and in 72.8% of cases of eP (P = 0.14). PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma. |
| publishDate |
2017 |
| dc.date.none.fl_str_mv |
2 2017-01-01 2017 2017-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/289120 https://dx.doi.org/urn:doi:10.1002/cam4.1242 |
| url |
https://ddd.uab.cat/record/289120 https://dx.doi.org/urn:doi:10.1002/cam4.1242 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869402470400131072 |
| score |
15,301603 |